freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-17. Anything still debated is marked as such rather than presented as settled.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
Light exposure can damage aromatic residues and certain labels, so amber vials or opaque containers are often used. pH control matters in solution, as extreme acidity or alkalinity accelerates backbone cleavage; buffers may also introduce ions that affect solubility. Microbial growth is a concern for aqueous preparations that lack preservatives, though many research peptides are handled in sterile or low-bioburden conditions. Container materials can adsorb peptides, particularly hydrophobic or positively charged sequences, reducing recovery. These factors interact, meaning storage decisions balance chemical stability, physical state, and intended use.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, and conformation. The amide backbone can hydrolyze under acidic or basic conditions, while side chains such as methionine, cysteine, and tryptophan are prone to oxidation. Aggregation may occur when hydrophobic regions associate, especially near surfaces or at high concentration. Because these pathways differ among peptides, no single storage condition applies to all sequences. Stability studies therefore examine each peptide under defined temperature, pH, and humidity ranges.
Temperature is a primary variable because most degradation reactions slow as thermal energy decreases. Lyophilized powders are commonly held at -20 °C for routine work and at -80 °C for longer archival periods, though exact recommendations depend on the peptide. Solutions are less stable than dry powders in many cases, and repeated freeze-thaw cycles can promote aggregation or precipitation. Inert atmospheres, such as argon or nitrogen, can limit oxidation for oxygen-sensitive sequences. Desiccants reduce water activity, which lowers hydrolysis rates during storage.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (lyophilized) | -20°C | Stable for months to years; avoid frost-free freezers |
| Storage temperature (solution) | -80°C | Single-use aliquots preferred; avoid repeated freeze-thaw |
| Reconstitution solvent | Sterile water or buffer | Choice depends on peptide solubility and application |
| Container material | Glass or polypropylene | Low protein-binding surfaces reduce adsorption |
| Shipping condition | Dry ice | Insulated packaging maintains cold chain during transit |
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
Water is a central factor in peptide degradation because it enables hydrolysis and mobilizes reactive species. Lyophilized or dry powders typically remain stable for longer than solutions when kept cool and dry. Oxygen can drive oxidation, particularly for sulfur-containing residues, while light can catalyze side-chain damage. Buffer choice and pH influence charge state and can accelerate or slow deamidation and aggregation. Freeze-thaw cycles may concentrate solutes or promote ice-induced aggregation, so minimizing such cycles is a common handling goal.
Lyophilization removes water under vacuum from a frozen solution, leaving a porous cake or powder. Formulation excipients such as sugars or polyols can stabilize structure during freezing and drying and can raise the glass transition temperature. Residual moisture in the final product remains a critical variable because even small amounts can support hydrolysis over time. Storage recommendations often specify desiccation, darkness, and low temperature, though exact conditions depend on the peptide and its intended use. Stability studies measure changes under defined conditions rather than predicting absolute shelf life.
Peptides are short chains of amino acids linked by amide bonds. Their stability depends on sequence, length, and the chemical environment. Common degradation routes include hydrolysis of the peptide backbone, oxidation of methionine or cysteine residues, deamidation of asparagine or glutamine, and aggregation through hydrophobic or electrostatic interactions. These processes can alter mass, charge, or biological activity, so storage conditions aim to slow them. The relative importance of each route varies widely among peptides.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
Phlebotonics of heterogeneous composition, consisting partly of citrus peel extracts (flavonoids, such as hesperidin) and synthetic compounds, are used to treat chronic venous insufficiency and hemorrhoids. Some are non-prescription dietary supplements, such as diosmin, while one other – Vasculera (Diosmiplex) – is a prescription medical food intended for treating venous disorders. Their mechanism of action is undefined, and clinical evidence of benefit for using phlebotonics to treat venous diseases is limited.
Here, Cl is the total concentration of all polynucleotide chains belonging to a hypercycle Hl, C is the total concentration of polynucleotide chains belonging to all hypercycles, ql is the rate of growth, and φ is a dilution flux that guarantees that the total concentration is constant. According to the above model, in the initial phase, when several hypercycles exist, the selection of the hypercycle with the largest ql value takes place. When one hypercycle wins the selection and dominates the population, it is very difficult to replace it, even with a hypercycle with a much higher growth rate q.
(Feb 2011) found that, "The increase in zeaxanthin appears to surpass the decrease in violaxanthin in spinach" and commented that the discrepancy could be explained by "a synthesis of zeaxanthin from beta-carotene", however they noted further study is required to explore this hypothesis.
Until recently, it was believed that the earliest ancient Egyptian mummies were created naturally due to the environment in which they were buried. In 2014, an 11-year study by the University of York, Macquarie University and the University of Oxford suggested that artificial mummification occurred 1,500 years earlier than first thought. This was confirmed in 2018, when tests on a 5,600-year-old mummy in Turin revealed that it had been deliberately mummified using linen wrappings and embalming oils made from conifer resin and aromatic plant extracts. The preservation of the dead had a profound effect on ancient Egyptian religion. Mummification was an integral part of the rituals for the dead beginning as early as the 2nd dynasty (about 2800 BC). Egyptians saw the preservation of the body after death as an important step to living well in the afterlife. As Egypt gained more prosperity, burial practices became a status symbol for the wealthy as well. This cultural hierarchy led to the creation of elaborate tombs, and more sophisticated methods of embalming. By the 4th dynasty (about 2600 BC) Egyptian embalmers began to achieve "true mummification" through a process of evisceration. Much of this early experimentation with mummification in Egypt is unknown. The few documents that directly describe the mummification process date to the Greco-Roman period. The majority of the papyri that have survived only describe the ceremonial rituals involved in embalming, not the actual surgical processes involved.
Central obesity: waist circumference ≥102 cm (40 in) men; ≥88 cm (35 in) women Dyslipidaemia: TG ≥1.7 mmol/L (150 mg/dL) Dyslipidaemia: HDL-C <40 mg/dL (men), <50 mg/dL (women) Blood pressure ≥130/85 mmHg (or treated for hypertension) Fasting plasma glucose ≥6.1 mmol/L (110 mg/dL)
Sources: en.wikipedia.org
=== Elevated levels === Hyperprolactinaemia, or excess serum prolactin, is associated with hypoestrogenism, anovulatory infertility, oligomenorrhoea, amenorrhoea, unexpected lactation and loss of libido in women and erectile dysfunction and loss of libido in men. Causes of Elevated Prolactin Levels
Tweezing (hairs are tweezed, or pulled out, with tweezers or with fingers) Waxing (a hot or cold layer is applied and then removed with porous strips) Sugaring (hair is removed by applying a sticky paste to the skin in the direction of hair growth and then peeling off with a porous strip) Threading (also called fatlah or khite in Arabic, or band in Persian) in which a twisted thread catches hairs as it is rolled across the skin Epilators (mechanical devices that rapidly grasp hairs and pull them out). Drugs that directly attack hair growth or inhibit the development of new hair cells. Hair growth will become less and less until it finally stops; normal depilation/epilation will be performed until that time. Hair growth will return to normal if use of product is discontinued. Products include the following: The pharmaceutical drug eflornithine hydrochloride (with the trade names Vaniqa and Follinil) inhibits the enzyme ornithine decarboxylase, preventing new hair cells from producing putrescine for stabilizing their DNA. Antiandrogens, including spironolactone, cyproterone acetate, flutamide, bicalutamide, and finasteride, can be used to reduce or eliminate unwanted body hair, such as in the treatment of hirsutism. Although effective for reducing body hair, antiandrogens have little effect on facial hair. However, slight effectiveness may be observed, such as some reduction in density/coverage and slower growth. Antiandrogens will also prevent further development of facial hair, despite only minimally affecting that which is already there.
MacDonald et al. (1990) has described four general community types. These are communities dominated by Vestimentiferan tube worms (Lamellibrachia c.f. barhami and Escarpia spp.), mytilid mussels (Seep Mytilid Ia, Ib, and III, and others), vesicomyid clams (Vesicomya cordata and Calyptogena ponderosa), and infaunal lucinid or thyasirid clams (Lucinoma sp. or Thyasira sp.). Bacterial mats are present at all sites visited to date. These faunal groups tend to display distinctive characteristics in terms of how they aggregate, the size of aggregations, the geological and chemical properties of the habitats in which they occur, and, to some degree, the heterotrophic fauna that occur with them. Many of the species found at these cold seep communities in the Gulf of Mexico are new to science and remain undescribed. Individual lamellibrachid tube worms, the longer of two taxa found at seeps, can reach lengths of 3 metres (9.8 feet) and live hundreds of years (Fisher et al., 1997; Bergquist et al., 2000). Growth rates determined from recovered marked tube worms have been variable, ranging from no growth of 13 individuals measured one year to a maximum growth of 9.6 cm/yr (3.8 in/yr) in a Lamellibrachia individual (MacDonald, 2002). Average growth rate was 2.19 cm/yr (0.86 in/yr) for the Escarpia-like species and 2.92 cm/yr (1.15 in/yr) for lamellibrachids. These are slower growth rates than those of their hydrothermal vent relatives, but Lamellibrachia individuals can reach lengths 2–3 times that of the largest known hydrothermal vent species. Individuals of Lamellibrachia sp.
Poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) is a composite material where PEDOT (the conductive polymer) provides electrical conductivity, and PSS (polystyrene sulfonate) acts as a counter-ion to balance the charge and improve the water solubility and processability of PEDOT. Polystyrene sulfonate is a sulfonated polystyrene. Part of the sulfonyl groups are deprotonated and carry a negative charge. The other component poly(3,4-ethylenedioxythiophene) (PEDOT) is a conjugated polymer and carries positive charges and is based on polythiophene. Together the charged macromolecules form a macromolecular salt.
Research in mice has shown that beta cells can often regenerate to the original quantity number after the beta cells have undergone some sort of stress test, such as the intentional destruction of the beta cells in the mice subject or once the auto-immune response has concluded. While these studies have conclusive results in mice, beta cells in human subjects may not possess this same level of versatility. Investigation of beta cells following acute onset of Type 1 diabetes has shown little to no proliferation of newly synthesized beta cells, suggesting that human beta cells might not be as versatile as rat beta cells, but there is actually no comparison that can be made here because healthy (non-diabetic) rats were used to prove that beta cells can proliferate after intentional destruction of beta cells, while diseased (type-1 diabetic) humans were used in the study which was attempted to use as evidence against beta cells regenerating. It appears that much work has to be done in the field of regenerating beta cells. Just as in the discovery of creating insulin through the use of recombinant DNA, the ability to artificially create stem cells that would differentiate into beta cells would prove to be an invaluable resource to patients with Type 1 diabetes. An unlimited amount of beta cells produced artificially could potentially provide therapy to many of the patients who are affected by Type 1 diabetes.
Sources: en.wikipedia.org
Variations in both the BDNF and BDNF-AS genes are important factors to consider, given their potential to alter BDNF function and contribute to multiple human phenotypes influencing disease susceptibility and treatment outcomes.
=== Antagonists and inverse agonists === Non-selective Agouti-related peptide Agouti signalling peptide MC2-selective Atumelnant (CRN04894) MC4-selective HS-014 HS-024 MCL-0042 MCL-0129 MPB-10 SHU-9119 (agonist at MC1 and MC5, antagonist at MC3 and MC4)
nebeprisikiškiakopūstlapiaujančiuosiuose – "in those, of masculine gender, who aren't gathering enough wood sorrel's leaves by themselves anymore." – the plural locative case of past iterative active participle of verb kiškiakopūstlapiauti meaning "to pick wood-sorrels' leaves" (leaves of edible forest plant with sour taste, word by word translation "rabbit cabbage"). The word is attributed to software developer / writer Andrius Stašauskas.
==== Humans ==== Gene therapy uses genetically modified viruses to deliver genes which can cure disease in humans. Although gene therapy is still relatively new, it has had some successes. It has been used to treat genetic disorders such as severe combined immunodeficiency, and Leber's congenital amaurosis. Treatments are also being developed for a range of other currently incurable diseases, such as cystic fibrosis, sickle cell anemia, Parkinson's disease, cancer, diabetes, heart disease and muscular dystrophy. These treatments only effect somatic cells, meaning any changes would not be inheritable. Germline gene therapy results in any change being inheritable, which has raised concerns within the scientific community. In 2015, CRISPR was used to edit the DNA of non-viable human embryos. In November 2018, He Jiankui announced that he had edited the genomes of two human embryos, in an attempt to disable the CCR5 gene, which codes for a receptor that HIV uses to enter cells. He said that twin girls, Lulu and Nana, had been born a few weeks earlier and that they carried functional copies of CCR5 along with disabled CCR5 (mosaicism) and were still vulnerable to HIV. The work was widely condemned as unethical, dangerous, and premature.
Sources: en.wikipedia.org
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.
Solutions are typically stored at -80°C in single-use aliquots to avoid repeated freeze-thaw cycles. They should be protected from light and kept in low-binding containers. Some peptides require a carrier protein or cryoprotectant to prevent adsorption and aggregation.
Records should include the lot number, date received, storage temperature, and any handling steps. A log of freeze-thaw cycles and aliquot preparation helps track stability. This documentation supports traceability and quality control.
Freezing slows hydrolysis and oxidation by reducing molecular motion and available water. Lyophilized powders contain little moisture, so they can remain stable for extended periods when kept cold and dry. The exact temperature depends on peptide sequence and expected storage duration.